FindTrial
Sign In

An Open-label, Multicenter, Randomized, 3 Arm Study of S-1 Compared With S-1/CDDP, or S-1/CDDP Compared With 5-FU/CDDP in Patients With Advanced Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease.

An Open-label, Multicenter, Randomized, 3 Arm Study of S-1 Compared With S-1/CDDP, or S-1/CDDP Compared With 5-FU/CDDP in Patients With Advanced Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220049
Enrollment
Unknown
Registered
2005-09-07
Start date
2005-09-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer

Interventions

investigational material(s) Generic name etc : S-1 (tegafur + gimeracil + oteracil potassium), CDDP INN of investigational material : S-1:tegafur, gimeracil, oteracil potassium, CDDP:cisplatin Therap

Sponsors

Taiho Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Non-prior chemotherapy treated advanced gastric cancer. 2)Non-resectable, locally-advanced or metastatic gastric cancer which is histologically confirmed adenocarcinoma.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Antitumor effect and time to treatment failure—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026